Microarrays in pharmacogenomics - Advances and future promise

Pharmacogenomics

Volumn 3, Issue 5, 2002, Pages 589-601

  Chicurel, Marina E ^a   Dalma Weiszhausz, Dennise D ^a  

^a NONE   (United States)

Author keywords

DNA arrays; Expression profiling; Genomics; Genotyping; Oligonucleotide microarrays; Pharmacogenomics; SNP

Indexed keywords

3 METHYLCHOLANTHRENE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CLOFIBRATE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IMATINIB; PHENOBARBITAL; TAMOXIFEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA MICROARRAY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EXPRESSED SEQUENCE TAG; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOMIC IN SITU HYBRIDIZATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PHARMACOGENOMICS; PROGNOSIS; PROSTATE CANCER; REVIEW; SEQUENCE DATABASE; SINGLE NUCLEOTIDE POLYMORPHISM;

GENE EXPRESSION; GENOTYPE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PHENOTYPE;

EID: 0036739330     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.5.589     Document Type: Review

References (78)

1. Carson P, Flanagan C, Ickes C, Alving A: Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124, 484-485 (1956).
2. Hughes H, Biehl J, Jones A, Schimdt L: Metabolism of isoniazid in man as related to occurrence of peripheral neuritis. Am. Rev. Tuberc. 70, 266-273 (1954).
3. Spannbrucker N, Eichelbaum M, Steinke B, Dengler HJ: A human genetic defect in the metabolism of sparteine. Verh. Dtsch. Ges. Inn. Med. 84, 1125-1127 (1978).
4. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586 (1977).
5. Gonzalez FJ, Skoda RC, Kimura S et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442-446 (1988).
6. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat. Rev. Cancer 1, 99-108 (2001).
7. Vogel F: Moderne probleme der humangenetik. Ergebnisse Inneren Medizin Keinderheilkunde 12, 52-125 (1959).
8. Weinstein JN: Searching for pharmacogenomic markers: the synergy between omic and hypothesis-driven research. Dis. Markers 17, 77-88 (2001).
9. McLeod HL, Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Ann. Rev. Pharmacol. Toxicol. 41, 101-121 (2001).
10. Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Ann. Rev Genomics Hum. Genet. 2, 9-39 (2001).
11. Austin F. Kreiner T: Integrating genomics technologies in healthcare: practice and policy challenges and opportunities. Physiol, Genomics 8, 33-40 (2002).
12. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm. Sci. 2, E29 (2000).
13. Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
14. Chicurel ME, Dalma-Weiszhausz DD: Tools for decoding cancer's molecular signatures: oligonucleotide microarrays. In: Expression profiling of human tumours. Ladanyi M, Gerald W (Eds), Humana Press, Inc., Totowa, NJ, USA (2002) In press.
15. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
16. Notterman DA, Alon U, Sierk AJ, Levine AJ: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma and normal tissue examined by oligonucleotide arrays. Cancer Res. 61, 3124-3130 (2001).
17. Couzin J: Genomics. New mapping project splits the community. Science 296, 1391-1393 (2002).
18. Weiss KM, Terwilliger JD: How many diseases does it take to map a gene with SNPs? Nat. Genet. 26, 151-157 (2000).
19. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet. Med. 4, 45-61 (2002).
20. Gabriel SB, Schaffner SF, Nguyen H et al.: The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
21. The Chipping Forecast. Nat. Genetics 21, (1999).
22. Blohm DH, Guiseppi-Elie A: New developments in microarray technology. Curr. Opin. Biotechnol. 12, 41-47 (2001).
23. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic oligonucleotide arrays. Nat. Genet. 21, 20-24 (1999).
24. Lockhart DJ, Winzeler EA: Genomics, gene expression and DNA arrays. Nature 405, 827-836 (2000).
25. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D: Light-directed, spatially addressable parallel chemical synthesis. Science 251, 767-773 (1991).
26. Ramaswamy S, Golub TR: DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002).
27. Druker BJ, Sawyers CL, Kantarjian H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Engl J. Med. 344, 1038-1042 (2001).
28. Druker BJ, Talpaz M, Resta DJ et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic mycloid leukaemia. N. Engl. J. Med. 344, 1031-1037 (2001).
29. Golub TR, Slonim DK, Tamayo P et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
30. Armstrong SA, Staunton JE, Silverman LB et al.: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukaemia. Nat. Genet. 30, 41-47 (2002).
31. Yeoh E-J, Ross M, Shurtleff S et al.: Classification, subtype discovery and prediction of outcome in pediatric acute lymphoblastic leukaemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
32. Shipp MA, Ross KN, Tamayo P et al.: Diffuse large B cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68-74 (2002).
33. Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535 (2000).
34. West M, Blanchette C, Dressman H et al.: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98, 11462-11467 (2001).
35. Bhattacharjee A, Richards WG, Staunton J et al.: Classification of human lung carcinomas by mRNA expression analysis. Proc. Natl Acad. Sci. USA 98, 13790-13795 (2001).
36. Singh D, Febbo P, Ross K et al.: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209 (2002).
37. Stamey TA, Warrington JA, Caldwell MC et al.: Molecular genetic profiling of Gleason grade 4/5 prostatic cancers compared to benign prostatic hyperplasia. J. Urol. 166, 2171-1277 (2001).
38. Alevizos I, Mahadevappa M, Zhang X et al.: Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 20, 6196-6204 (2001).
39. Thykjaer T, Workman C, Kruhoffer M et al.: Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 61, 2492-2499 (2001).
40. Welsh JB, Zarrinkar PP, Sapinoso LM et al.: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 98, 1176-1181 (2001).
41. Graveel CR, Jatkoe T, Madore SJ, Holt AL, Farnham PJ: Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene 20, 2704-2712 (2001).
42. Tackels-Horne D, Goodman MD, Williams AJ et al.: Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumours by oligonucleotide expression profiling. Cancer 92, 395-405 (2001).
43. Golub TR: Genome-wide views of cancer. N. Engl. J. Med. 344, 601-602 (2001).
44. Alon U, Barkai N, Notterman DA et al.: Broad patterns of gene expression revealed by clustering analysis of tumour and normal colon tissues probed by oligonucleotide arrays. Proc. Natl Acad. Sci. USA 96, 6745-6750 (1999).
45. Scherf U, Ross DT, Waltham M et al.: A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244 (2000).
46. Ross DT, Scherf U, Eisen MB et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235 (2000).
47. Staunton JE, Slonim DK, Coller HA et al.: Chemosensitiviry prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-10792 (2001).
48. Hu JS, Durst M, Kerb R et al.: Analysis of drug pharmacology towards predicting drug behavior by expression profiling using high-density oligonucleotide arrays. Ann. NY Acad. Sci. 919, 9-15 (2000).
49. Jin HMD, Yang RMD, Awad TAP et al.: Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation 103, 736-742 (2001).
50. Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK: Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proc. Natl Acad. Sci. USA 99, 1461-1466 (2002).
51. Gerhold D, Lu M, Xu J, Austin C, Caskey CT, Rushmore T: Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol. Genomics, 5, 161-170 (2001).
52. Cheok M, Yang M, Shipman M et al.: Treatment-specific changes in gene expression in primary leukaemia cells, in vivo, during initial therapy for acute lymphoblastic leukaemia (ALL). 93rd Annual Meeting of the American Association of Cancer Res. Abstract (LB 171), (2002).
53. Perou CM, Jeffrey SS, van de Rijn M et al.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl Acad. Sci. USA 96, 9212-9217 (1999).
54. Gruvberger S, Ringner M, Chen Y et al.: oestrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001).
55. Martin KJ, Kritzman BM, Price LM et al.: Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 60, 2232-2238 (2000).
56. Zajcowski DA, Bartholdi MF, Gong Y et al.: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 61, 5168-5178 (2001).
57. Sorlie T, Peron CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
58. van't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
59. Alizadeh AA, Eisen MB, Davis RE et al.: Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
60. Staudt L: It's ALL in the diagnosis. Cancer Cell 1, 109-110 (2002).
61. Hogenesch JB, Ching KA, Batalov S et al.: A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes. Cell 106, 413-415 (2001).
62. Liotta L, Petricoin E: Molecular profiling of human cancer. Nat. Rev. Genet. 1, 48-56 (2000).
63. Innocenti F, Ratain MJ: Update on pharmacogenetics in cancer chemotherapy. Eur. J. Cancer 38, 639-644 (2002).
64. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
65. Kwok PY: Methods for genotyping single nucleotide polymorphisms. Ann. Rev Genomics Hum. Genet. 2, 235-258 (2001).
66. Dalma-Weiszhausz D, Chicurel M, Gingeras T: Microarrays and genetic epidemiology: a multi-purpose tool for a multi-faceted field. Genetic Epidemiol. 23, 4-20 (2002).
67. Cronin MT, Fucini RV, Kim SM, Masino RS, Wespi RM, Miyada CG: Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays. Hum. Mutat. 7, 244-255 (1996).
68. Murphy GM Jr, Pollock BG, Kirshner MA et al.: CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25, 737-743 (2001).
69. Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS: Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat. Genetics 14, 441-447 (1996).
70. Sachidanandam R, Weissman D, Schmidt SC et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
71. Cutler DJ, Zwick ME, Carrasquillo MM et al.: High-throughput variation detection and genotyping using microarrays. Genome Res. 11, 1913-1925 (2001).
72. Patil N, Berno AJ, Hinds DA et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294, 1719-1723 (2001).
73. Kwok PY: GENOMICS: genetic association by whole-genome analysis? Science 294, 1669-1670 (2001).
74. Relling MV, Rubnitz JE, Rivera GK et al.: High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354, 34-39 (1999).
75. Tice DA, Szeto W, Soloviev I et al.: Synergistic induction of tumour antigens by wnt- 1 signalling and retinoic acid revealed by gene expression profiling. J. Biol. Chem. 277, 14329-14335 (2002).
76. Ferrando A, Neuberg D, Staunton J et al.: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukaemia. Cancer Cell 1, 75-87 (2002).
77. Szeto W, Jiang W, Tice DA et al.: Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res. 61, 4197-4205 (2001).
78. Dalma-Weiszhausz D, Murphy GM: Single basepair polymorphisms and their characterization with oligonucleotide microarrays. Psychiatric Genetics 12, 97-107 (2002).